SMARCA2 and central nervous system cancer: The phosphoproteome data detected 1212 differentially expressed phosphosites in the BrM/BrM‐NAT group and 437 in the Glioma/Glioma‐NAT group, 193 of which showed concordant regulation in the two groups (Figure 2C; Figure S4D–F; Table S2, Supporting Information).